![Manchester tech company celebrates 30 years of being at the heart of the North West's technological revolution - Manchester Evening News Manchester tech company celebrates 30 years of being at the heart of the North West's technological revolution - Manchester Evening News](https://cdn.jwplayer.com/v2/media/m0Jn5iXD/poster.jpg)
Manchester tech company celebrates 30 years of being at the heart of the North West's technological revolution - Manchester Evening News
![DEVELOPMENT OF A BIOLOGICALLY-RELEVANT PRECLINICAL RADIOTHERAPY DOSIMETRY PHANTOM (Manchester eScholar - The University of Manchester) DEVELOPMENT OF A BIOLOGICALLY-RELEVANT PRECLINICAL RADIOTHERAPY DOSIMETRY PHANTOM (Manchester eScholar - The University of Manchester)](https://www.escholar.manchester.ac.uk/jrul/resources/Main-Structure_files/about.jpg)
DEVELOPMENT OF A BIOLOGICALLY-RELEVANT PRECLINICAL RADIOTHERAPY DOSIMETRY PHANTOM (Manchester eScholar - The University of Manchester)
![Manchester tech company celebrates 30 years of being at the heart of the North West's technological revolution - Manchester Evening News Manchester tech company celebrates 30 years of being at the heart of the North West's technological revolution - Manchester Evening News](https://i2-prod.manchestereveningnews.co.uk/incoming/article24163475.ece/ALTERNATES/s1200d/0_ILM_Sync_160421-17.jpg)
Manchester tech company celebrates 30 years of being at the heart of the North West's technological revolution - Manchester Evening News
![GBM Group's investment in high-speed Screen Truepress Jet W3200UV printer triples capacity and wins business - SCREEN Europe GBM Group's investment in high-speed Screen Truepress Jet W3200UV printer triples capacity and wins business - SCREEN Europe](https://www.screeneurope.com/wp-content/uploads/2017/09/53.jpg)
GBM Group's investment in high-speed Screen Truepress Jet W3200UV printer triples capacity and wins business - SCREEN Europe
![A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma | British Journal of Cancer A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-021-01259-3/MediaObjects/41416_2021_1259_Fig1_HTML.png)